Key result
A transcatheter pulmonary valve with bioengineered tissue leaflets implanted in 5 juvenile sheep for up to 18 months showed no loss of function, no regurgitation, and mild calcification.
Why the study?
Congenital valve disease requires multiple replacements because current bioprosthetic valves degrade and calcify, prompting evaluation of an allogenic, decellularized bioengineered tissue valve to provide an ideal solution for young patients.
Does a transcatheter pulmonary valve with bioengineered tissue leaflets maintain function and resist deterioration in a juvenile sheep model?
Does a transcatheter pulmonary valve with bioengineered tissue leaflets maintain function and resist deterioration in a juvenile sheep model?
A transcatheter pulmonary valve with bioengineered tissue leaflets maintained excellent hemodynamic function and showed no tissue deterioration over 18 months in a juvenile sheep model, suggesting potential as a durable alternative for young patients.
Answers are grounded in this paper and cite their sources.
Supports initial feasibility of bioengineered pulmonary valve in congenital disease; leaves open durability and adoption pending larger trials.
Congenital valve disease, predominantly in the pulmonary position, requires multiple replacements as current bioprosthetic valves degrade and calcify over time. An allogenic, decellularized bioengineered tissue with minimum immune response and calcification would provide an ideal solution for young patients and could substantially improve the standard of care. In this study, a transcatheter pulmonary valve with bioengineered tissue leaflets on a self-expanding nitinol stent was implanted for up to 18 months in five juvenile sheep using an 18Fr transapical delivery system. Serial echo monitoring showed an increase in cardiac output as the juvenile sheep grew without any decrease in effective orifice area (>2 cm 2 ) or increase in pressure gradients (<10 mmHg for both peak and mean). No valvular regurgitation, leaflet thickening, or tissue abnormality was reported at any time points. Micro-CT and histological assessment showed mild calcification and mild thrombosis. The 18-month implants in the highly calcific juvenile sheep model showed no loss of function and no deterioration of the bioengineered tissue, suggesting a suitable alternative leaflet material for younger patients where functional longevity is critical.
No takes yet. Share an insight, caveat, or question.
McMahon et al. (2025) studied Congenital valve disease (animal model) (n=5). Transcatheter pulmonary valve with bioengineered tissue leaflets was evaluated on Valve function and tissue deterioration (effective orifice area, pressure gradients, regurgitation, calcification, thrombosis). A transcatheter pulmonary valve with bioengineered tissue leaflets implanted in 5 juvenile sheep for up to 18 months showed no loss of function, no regurgitation, and mild calcification.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: